


A detailed microscopic image showing a cluster of cancer cells. The cells are spherical and have a textured, bumpy surface, colored in shades of blue, purple, and pink. They are surrounded by a complex, porous network of yellow and orange tissue, which appears to be part of a larger organ or structure.

Humanity's most  
challenging diseases...

A circular inset image showing a DNA double helix structure. The DNA is represented by a series of colorful, overlapping bands in shades of blue, red, yellow, and green, forming a spiral pattern. A glass dropper is positioned above the DNA, with a single drop of liquid falling onto it, creating a small splash and ripples in the liquid below.

Meet a radical new way  
of conducting clinical trials

Cancer  
meets its match



# Omico is changing the way we fight cancer by accelerating access to precision oncology

**We are a national, independent, not-for-profit organisation**, uniting Australia's world-class cancer institutes, researchers, industry partners and government like never before.

By leveraging a nationwide network of expertise and resources, we aim to **improve outcomes for all Australian cancer patients** through facilitating clinical trials and pioneering the use of genomic and molecular screening for prevention and treatment of cancer.

Our pioneering, collaborative model will also position **Australia globally as a premier hub for cancer research.**




# We aim to improve outcomes for Australians with cancers, by



## Accelerating the use of precision oncology

Use genomic profiling to detect unique genetic variations in cancer patients' tumours to **identify potential new targeted treatments options**



## Growing clinical trials

Streamline biomarker-led clinical trials by **expediting patient recruitment and site setup, and attracting more international trials to Australia**



## Modernising the Australian healthcare system

Advance a **research-led model of care** to open new treatment pathways for patients

Advance drug development and cancer research through the **collection of real-world data**





# Adding value to all our partners

**Industry:** Reduce the cost and time needed for precision oncology clinical trials


**Researchers:** Greater innovation through genomic profiling and access to a national network of thought leaders to expand capabilities and knowledge base

**Clinicians:** Enhance your ability to make personalized treatment decisions by accessing comprehensive genomic profiling for your patients, providing valuable information to inform their care

**Patients:** Free genomic screening that may unlock new targeted treatment pathways for cancers

**Government:** Generate economic growth and attract more global investors in the Australian research sector, and improve patient outcomes

**Advocacy Groups:** Shared vision to ensure equitable opportunities for all patients to benefit from the latest advances in genomics and targeted treatments, to improve outcomes




How can we make  
your biomarker-led  
clinical trials easier,  
faster and feasible?

# Omico makes finding the *right* patients for your trials easier and faster

## Traditional model

Currently industry bears the cost of conducting standard biomarker screening to identify patients with specific biomarkers per trial




**Cost/test = \$500**

**\$10 million in screening costs to identify 200 patients\***

## Collaborative model

Omico uses comprehensive genomic profiling (CGP) to identify multiple biomarkers for **multiple trials at once**



**Cost/test = \$2,500**

**\$10 million in screening costs to identify 400 patients\***

**Omico can help identify patients more efficiently through our national screening platform.**

\*Assumption: biomarker present in the population at a 1% frequency.


Lu, C.Y., Terry, V. & Thomas, D.M. Precision medicine: affording the successes of science. *npj Precis. Onc.* **7**, 3 (2023). <https://doi.org/10.1038/s41698-022-00343-y>



# With Omico, increase clinical trial efficiency and reduce costs

## Traditional model

Only local site patient catchment population available; limited/no institutional screening




## Omico's Collaborative model

Strategically selected sites, accepting referred national patients



Open trials at fewer sites, faster

Leverage our national screening platform to identify and refer patients to your selected sites for recruitment



Improve clinical trial efficiency

PrOSPeCT is our landmark  
precision oncology initiative





# Precision Oncology Screening Platform Enabling Clinical Trials

Over 27 months, PrOSPeCT's Cancer Screening Program (CaSP) will provide free genomic profiling to **23,000 Australians with advanced or incurable cancers** and identify **potential matches for patients to clinical trials with new targeted therapies.**

This is the **largest cancer genomics initiative** in Australia.



# PrOSPeCT is anticipated to **drive growth** for the Australian research sector

## PrOSPeCT is expected to:



ATTRACT

**\$525M**

New direct investment in locally based clinical trials



SAVE

**\$135M**

Savings from avoided health interventions (medicines, tests, hospitals)



CREATE

**>650**

Jobs created in genomics, clinical trials and diagnostics in two years

# PrOSPeCT will position Australia as a premier hub for cancer research



Enabled by unique  
public-private funding  
and collaborative  
partnerships



Harnessing the  
combined expertise  
and resources of an  
established national  
network



Provide free CGP\*  
to 23,000 patients  
with advanced or  
incurable cancers

**CaSP**  
Cancer Screening Program



Advance drug  
development and  
cancer research with  
real-world data  
insights

\*Comprehensive Genomic Profiling (CGP)

# PrOSPeCT is enabled by public-private funding and partnerships



**\$185M**

public-private funding  
and partnerships



## PrOSPeCT Foundation Partners



Australian Government

(\$61.2M as part of the Modern  
Manufacturing Strategy)





NSW  
GOVERNMENT


(\$25M)




# PrOSPeCT leverages expertise and resources across our national network


Our established collaborative network is continuously growing, further expanding Australia's research capabilities and capacity








Trials	Data Analytics
<ul style="list-style-type: none"><li>• Global and local industry</li><li>• Small and large pharmaceutical companies</li><li>• Biotech</li><li>• Diagnostics</li><li>• Pathology services</li><li>• Health insurers</li><li>• Satellite industries</li><li>• CROs</li><li>• CMOs</li><li>• Workforce training and education</li></ul>	<ul style="list-style-type: none"><li>• Industry</li><li>• Data analytics companies</li><li>• Small and large biotech</li><li>• Pharmaceutical companies</li><li>• Government</li><li>• Regulatory</li><li>• Health</li><li>• Medical research</li></ul>





# PrOSPeCT's CaSP provides free genomic profiling to 23,000 Australians with advanced or incurable cancers



# PrOSPeCT will advance drug development and research with **real-world data insights**

Planned data integration to enhance analytic scope for richer healthcare insights



**CaSP data will be linked to AIHW, PBS, MBS, and patient's medical records**



**Demographics and lifestyle data**

**Pathology and treatment data**

**Comprehensive genomic profiling data**

**Follow-up data**

**CaSP**  
Cancer Screening Program



Enhanced data insights shape future healthcare innovations, research and publications



**Real-world evidence generation**

# Why partner with Omico?



## **Faster identification of eligible patients for your clinical trials**

Accelerate patient recruitment through our national screening platform, saving you time and money



## **Optimise your clinical trial set up**

Receive our guidance on strategic site selection for fewer sites and faster activation



## **Make your trials possible**

Facilitate clinical trials that may have previously been impossible due to low patient numbers



## **Tap into our knowledge, expertise and experience**

Draw on Omico's experience, data and network to support feasibility planning



## **Turn real-world data into real-time insights**

Leverage our real-world database to inform future research and innovations

# Together, cancer meets its match

Learn more about  
partnering with Omico.

**Contact us at [contact@omico.org.au](mailto:contact@omico.org.au)**

**W:** [Omico.com.au](http://Omico.com.au) **T:** 1800 954 350 **E:** [contact@omico.org.au](mailto:contact@omico.org.au)

© Copyright 2024. Australian Genomic Cancer Medicine Centre Ltd, trading as Omico, is a not-for-profit company limited by guarantee. Hilmer Building (E10), Union Rd, UNSW, Kensington, NSW, 2052.

Cancer  
**meets its match**

